Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Revolution Medicines's RMC-6291?
RMC-6291 is a small molecule commercialized by Revolution Medicines, with a leading Phase II program in Non-Small Cell Lung Cancer....
RMC-6291 by Revolution Medicines for Non-Small Cell Lung Cancer: Likelihood of Approval
RMC-6291 is under clinical development by Revolution Medicines and currently in Phase II for Non-Small Cell Lung Cancer. According to...
RMC-6291 by Revolution Medicines for Solid Tumor: Likelihood of Approval
RMC-6291 is under clinical development by Revolution Medicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase...